0
Original Research: Bronchiectasis |

A Preliminary Quality of Life Questionnaire-BronchiectasisQuality of Life Questionnaire-Bronchiectasis: A Patient-Reported Outcome Measure for Bronchiectasis

Alexandra L. Quittner, PhD; Kristen K. Marciel, PhD; Matthias A. Salathe, MD, FCCP; Anne E. O’Donnell, MD, FCCP; Mark H. Gotfried, MD, FCCP; Jonathan S. Ilowite, MD, FCCP; Mark L. Metersky, MD, FCCP; Patrick A. Flume, MD; Sandra A. Lewis, MS; Matthew McKevitt, PhD; A. Bruce Montgomery, MD; Thomas G. O’Riordan, MD; Alan F. Barker, MD, FCCP
Author and Funding Information

From the Department of Psychology and Pediatrics (Drs Quittner and Marciel), and the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine (Dr Salathe), Department of Medicine, University of Miami, Coral Gables, FL; the Division of Pulmonary, Critical Care and Sleep Medicine (Dr O’Donnell), Department of Medicine, Georgetown University, Washington, DC; Pulmonary Associates (Dr Gotfried), and University of Arizona (Dr Gotfried), Phoenix, AZ; the Department of Medicine (Dr Ilowite), Division of Pulmonary and Critical Care, Winthrop University Hospital, Mineola, NY; the Division of Pulmonary and Critical Care (Dr Metersky), University of Connecticut School of Medicine, University of Connecticut, Farmington, CT; the Division of Pulmonary and Critical Care Medicine (Dr Flume), Medical University of South Carolina, Charleston, SC; Gilead Sciences (Ms Lewis and Drs McKevitt, Montgomery, and O’Riordan), Seattle, WA; ; Cardeas Pharma (Dr Montgomery), Seattle, WA; and the Department of Medicine (Dr Barker), Division of Pulmonary and Critical Care, Oregon Health and Science University, Portland, OR.

CORRESPONDENCE TO: Alexandra L. Quittner, PhD, Child Division, University of Miami, 5665 Ponce de Leon Blvd, Coral Gables, FL 33146; e-mail: AQuittner@Miami.edu


FUNDING/SUPPORT: The studies described here were sponsored by Gilead Sciences, Inc and Behavioral Health Systems Research.

Part of this article has been presented previously in abstract form at American Thoracic Society International Conferences (May 19, 2009, San Diego, CA; May 19, 2010, New Orleans, LA; and May 20, 2013, Philadelphia, PA), a European Respiratory Society Annual Congress (September 13, 2009, Vienna, Austria), and CHEST conferences (October 30-November 4, 2010, Vancouver, BC, Canada; and October 22-26, 2011, Honolulu, HI).

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2014;146(2):437-448. doi:10.1378/chest.13-1891
Text Size: A A A
Published online

BACKGROUND:  The Quality of Life Questionnaire-Bronchiectasis (QOL-B) is the first disease-specific, patient-reported outcome measure for patients with bronchiectasis. Content validity, cognitive testing, responsivity to open-label treatment, and psychometric analyses are presented.

METHODS:  Reviews of literature, existing measures, and physician input were used to generate the initial QOL-B. Modifications following preliminary cognitive testing (N = 35 patients with bronchiectasis) generated version (V) 1.0. An open-ended patient interview study (N = 28) provided additional information and was content analyzed to derive saturation matrices, which summarized all disease-related topics mentioned by each participant. This resulted in QOL-B V2.0. Psychometric analyses were carried out using results from an open-label phase 2 trial, in which 89 patients were enrolled and treated with aztreonam for inhalation solution. Responsivity to open-label treatment was observed. Additional analyses generated QOL-B V3.0, with 37 items on eight scales: respiratory symptoms; physical, role, emotional, and social functioning; vitality; health perceptions; and treatment burden. For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life. No total score is calculated. A final cognitive testing study (N = 40) resulted in a minor change to one social functioning scale item (QOL-B V3.1).

RESULTS:  Content validity, cognitive testing, responsivity to open-label treatment, and initial psychometric analyses supported QOL-B items and structure.

CONCLUSIONS:  This interim QOL-B is a promising tool for evaluating the efficacy of new therapies for patients with bronchiectasis and for measuring symptoms, functioning, and quality of life in these patients on a routine basis. A final psychometric validation study is needed and is forthcoming.

TRIAL REGISTRY:  ClinicalTrials.gov; No.: NCT00805025; URL: www.clinicaltrials.gov

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543